Spectrum Pharma (SPPI) Tops Q4 EPS by 3c

Spectrum Pharma (NASDAQ: SPPI) reported Q4 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33).

“ROLONTIS is in active review by the FDA and we are preparing to launch shortly following approval,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “We believe this market represents a significant commercial opportunity and our prelaunch activities are well underway. We have a podium presentation on poziotinib in a few short weeks, we have taken steps to adjust our strategy and we have multiple data catalysts in 2020. I look forward to updating you on our progress throughout the year.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Rio Tinto reports 28% EBITDA rise, raises interim dividend 43%
• Fiverr International (FVRR) Misses Q2 EPS by 2c; updates guidance
• Deutsche Bank Aktiengesellschaft (DB) Misses Q2 EPS by 36c